Overview

An Open-Label Study of Emtricitabine in Combination With Other Antiretroviral Agents in HIV Infected Pediatric Subjects

Status:
Completed
Trial end date:
2004-07-01
Target enrollment:
Participant gender:
Summary
To obtain safety and efficacy data for antiretroviral regimens containing emtricitabine in HIV-1 infected pediatric subjects. To determine emtricitabine concentrations in HIV-1 infected pediatric subjects and, if necessary, to refine the dose of emtricitabine to achieve concentrations comparable to those in adults given 200 mg emtricitabine once-daily.
Phase:
Phase 2
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Anti-Retroviral Agents
Emtricitabine